FIELD: medicine.
SUBSTANCE: invention relates to medicine and is intended for the treatment of neoplasm associated with excessive expression or amplification of HER-2 in a subject. Combination of vinorelbine or a pharmaceutically acceptable salt thereof and (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide (HKI-272) or a pharmaceutically acceptable salt thereof is used.
EFFECT: method enables to increase the effectiveness of treatment and reduce the frequency of side effects of therapy.
28 cl, 3 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTINEOPLASTIC COMBINATIONS CONTAINING HKI-272 AND VINORELBINE | 2009 |
|
RU2492860C2 |
| ANTINEOPLASTIC COMBINATIONS OF 4-ANILINO-3-CYANOQUINOLINES AND CAPECITABINE | 2009 |
|
RU2498804C2 |
| ANTI-TUMOUR COMBINATIONS MTOR INHIBITORS, HERCEPTIN AND/OR HKI-272 | 2006 |
|
RU2451524C2 |
| TREATMENT REGIMEN FOR BREAST CANCER USING NERATINIB | 2019 |
|
RU2804713C2 |
| PROCESS FOR TREATMENT OF BREAST CANCER USING NERATINIB | 2014 |
|
RU2685715C2 |
| ANTITUMOUR COMBINATIONS WITH MTOR INHIBITORS, HERCEPTIN AND/OR HKI-272 | 2012 |
|
RU2632104C2 |
| METHOD OF TREATING CANCER CARRYING EGFR MUTATIONS | 2007 |
|
RU2492864C2 |
| METHOD OF TREATING GEFITINIB-RESISTANT CANCER | 2006 |
|
RU2405566C9 |
| COMBINATION OF OZOGAMICIN INOTUZUMAB AND TORIZEL FOR TREATING CANCER | 2012 |
|
RU2607594C2 |
| COMBINATION CONTAINING N-METHOXY-3-METHYLPYRAZINE-2-YL)-2-(4-[1,3,4-OXADIAZOL-2-YL]PHENYL)PYRIDINE-3-SULFONAMIDE AND ANTIMITOTIC SUBSTANCE FOR MALIGNANT GROWTH | 2005 |
|
RU2428188C2 |
